Home
Live Updates
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma : comparemela.com
First Patient Dosed in IPAX-2 Study of TLX101 Brain Cancer Therapy Candidate in Patients with Newly Diagnosed Glioblastoma
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase I study of the...
Related Keywords
New Zealand ,
Australia ,
Austria ,
United Kingdom ,
Melbourne ,
Victoria ,
Japan ,
Canada ,
United States ,
Switzerland ,
Belgium ,
Australian ,
Colin Hayward ,
Kyahn Williamson ,
Josef Pichler ,
Linkedin ,
Prnewswire Telix Pharmaceuticals Limited ,
Drug Administration ,
European Union ,
Health Canada ,
Telix Pharmaceuticals ,
Australian Therapeutic Goods Administration ,
Kepler University Hospital ,
Australian Securities Exchange ,
Corporate Communications ,
Pharmaceuticals Limited ,
Principal Investigator ,
Telix Chief Medical Officer ,
United States Food ,
Telix Pharmaceuticals Limited ,
comparemela.com © 2020. All Rights Reserved.